Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2023
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Pete Schmidt, MD
Invivyd, Inc.
Poster(s):
(1363) Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention
Friday, October 13, 2023
12:15 PM – 1:30 PM
US ET
